| 000 | 02646nam a2200337Ia 4500 | ||
|---|---|---|---|
| 003 | MX-MdCICY | ||
| 005 | 20250625160149.0 | ||
| 040 | _cCICY | ||
| 090 | _aB-16303 | ||
| 245 | 1 | 0 | _aStudies on the anti-diabetic and hypolipidemic potentials of mangiferin (xanthone glucoside)in streptozotocin-induced type 1 and type 2 diabetic model rats |
| 490 | 0 | _vInternational Journal of Advances in Pharmaceutical Sciences, 1(1), p.75-85, 2010 | |
| 520 | 3 | _aContext: Mangifera indica (Anacardiaceae)stem bark contains a rich content of mangiferin and is used traditionally in Indian Ayurvedic system to treat diabetes. Purpose of the study: To investigate anti-diabetic and hypolipidemic effects of mangiferin in type 1 and type 2 diabetic rats models. Streptozotocin was used to induce type 1 and type 2 diabetic rats. Mangiferin (at a dose 10 and 20mg/kg)was administrated intra-peritoneally in type 1 and type 2 diabetic rats daily up to 30 days. Biochemical parameters notably fasting blood sugar, total cholesterol, triglycerides, low-density lipoprotein, very low-density lipoprotein and high-density lipoprotein were estimated. In addition, in vitro alpha amylase and alpha glucosidase inhibitory effects of mangiferin were performed and IC50 values were determined. Results: Mangiferin exhibited significant (P<0.05)anti-diabetic as well as hypolipidemic effects by lowering FBS, TC, TG, LDL, and VLDL levels; but also with elevation of HDL level in type 2 diabetic model rats. In addition, mangiferin showed appreciable alpha amylase inhibitory effect (IC50 value 74.35±1.9µg/ml)and alpha glucosidase inhibitory effect (IC50 41.88±3.9µg/ml)when compared with standard drug acarbose (IC50 83.33±1.2µg/ml). Conclusions: Mangiferin showed anti-diabetic as well as hypolipidemic potentials in type 2 diabetic model rats. Therefore, mangiferin possess beneficial effects in the management of type 2 diabetes with hyperlipidemia. | |
| 650 | 1 | 4 | _aACARBOSE |
| 650 | 1 | 4 | _aALPHA GLUCOSIDASE |
| 650 | 1 | 4 | _aAMYLASE |
| 650 | 1 | 4 | _aCHOLESTEROL |
| 650 | 1 | 4 | _aGLIBENCLAMIDE |
| 650 | 1 | 4 | _aGLUCOSE |
| 650 | 1 | 4 | _aHIGH DENSITY LIPOPROTEIN |
| 650 | 1 | 4 | _aLOW DENSITY LIPOPROTEIN |
| 650 | 1 | 4 | _aMANGIFERIN |
| 650 | 1 | 4 | _aRECOMBINANT HUMAN INSULIN |
| 650 | 1 | 4 | _aTRIACYLGLYCEROL |
| 650 | 1 | 4 | _aVERY LOW DENSITY LIPOPROTEIN |
| 700 | 1 | 2 | _aDineshkumar, B. |
| 700 | 1 | 2 | _aMitra, A. |
| 700 | 1 | 2 | _aManjunatha, M. |
| 856 | 4 | 0 |
_uhttps://drive.google.com/file/d/1YBVh_YImOjysnrcv5Uq2IlibednqnKl1/view?usp=drivesdk _zPara ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx |
| 942 |
_2Loc _cREF1 |
||
| 008 | 250602s9999 xx |||||s2 |||| ||und|d | ||
| 999 |
_c50477 _d50477 |
||